Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 7/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 4/20 | 0.36 |
| ▸ | CNR1 | P21554 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL541487 | 0.86 | LRRK2 (0.39) | CNR2CNR1MEN1KMT2AALDH1A1 | |
| SCHEMBL10146173 | 0.82 | HDAC6 (0.39) | L3MBTL1EPHX2CNR2TSHRMEN1 | |
| SCHEMBL10145915 | 0.82 | CNR2 (0.44) | CYP2D6CNR2 | |
| SCHEMBL12796304 | 0.81 | EPHX2 (0.48) | EPHX2CYP2D6CNR2TSHR | |
| SCHEMBL15397167 | 0.80 | LRRK2 (0.36) | EPHX2CNR2CNR1MEN1KMT2A | |
| SCHEMBL15397213 | 0.80 | CNR2 (0.34) | CYP2D6CNR2 | |
| SCHEMBL12796705 | 0.79 | TSHR (0.38) | L3MBTL1EPHX2TSHRCHEK1MEN1 | |
| SCHEMBL12796699 | 0.79 | HDAC3 (0.35) | CYP2D6CNR2 | |
| SCHEMBL15397220 | 0.77 | CNR2 (0.41) | CYP2D6CNR2 | |
| SCHEMBL10145275 | 0.76 | TYRO3 (0.38) | L3MBTL1SIGMAR1TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8524727-B2 | Pyrimidine compound | ASTELLAS PHARMA INC. (JP) | 2013-09-03 | — | — | US | disclosed |
| US-20110053912-A1 | PYRIMIDINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-03-03 | — | — | US | disclosed |
| WO-2010113834-A1 | PYRIMIDINE COMPOUND | アステラス製薬株式会社 (JP) | 2010-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053912-A1 | PYRIMIDINE COMPOUND | CNR2, CNR1, P2RY2 | L3MBTL1 3546/4885EPHX2 339/4885SIGMAR1 720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.